Neurodegenerative Market Forecast to 2013

Summary

Comprehensive Forecasts for Neurodegenerative Conditions

The neurodegenerative space is a top-selling pharmaceutical market. Consider these facts:

• Sales among all drugs profiled in this report total $18.5 billion and are expected to increase 62% to $29.7 billion by 2012.
• The majority of this growth is projected to be in multiple sclerosis, which will increase from a $12.6 billion market to upwards of $20 billion in 2012.

Neurodegenerative disease patients have few treatment options, which often provide only limited effectiveness. Companies that can invest in and develop new, tolerable therapies which improve patients' quality of life could see hundreds of millions - or even billions - of dollars in sales.

In one convenient, easy-to-access format, Neurodegenerative Market Forecast to 2013 provides a compelling, full picture of the Alzheimer's, Multiple Sclerosis and Parkinson's markets.

Detailed Product Profiles

CEI's veteran analysts examine 40 brands representing different classes and stages of development. The profiled products represent over 90% of sales in the neurodegenerative market. Each drug profile has the following components:

• Drug history
• Competitive and strategic positioning:
• Current status of drug
• Sales position within its class
• Presence or strength of competition
• Market growth opportunities:
• Analysis combines new/current sales or clinical trial info with projections, predictions, insights
• Analysis supported by sales projection charts, covering up to the next 7 years
• Materiality charts, for 2007 and 2012
• Charts containing market exclusivity and patent information for approved drugs
• Clinical trial data tables to quickly show clinical detail:
• Describes trial and why drug is in its current stage
• Progress of drug

Analyses weigh the challenges and opportunities of each indication, class, and individual brand. Which brands will reap dividends and why? Whose sales are expected to drop? Which experimental therapies represent the next great medical breakthrough? Who will be the markets' leaders in the next decade?

More than 40 products from 25+ companies, including:

Eli Lilly /Pfizer
Wyeth/ Bristol-Myers Squibb
Biogen Idec/ Genentech
GlaxoSmithKline/ Novartis
AstraZeneca

Contents

• Profiled Brands in Alzheimer's, Multiple Sclerosis and Parkinson's
• Alzheimer's Disease
  • Anti-Amyloid Beta (Plaques)
    • Bapineuzumab / AAB-001
    • LY450139
    • LY2062430
    • ACC-001
  • Acetylcholinesterase Inhibitors
    • Aricept
    • Excelon
    • Razadyne
  • NMDA Antagonists
    • Namenda: alsknown as Ebixa in some EU countries
    • Ebixa: alsknown as Namenda in US
  • Other Alzheimer's Therapies Targeting Neurotransmitters
    • Abilify
    • Dimebon
    • AZD3480 / TC-1734
    • SB 742457
  • Other Alzheimer's Therapies
    • MEM1003
    • Tanakan
    • Avandia XR
• Multiple Sclerosis (MS)
  • Immunomodulators
    • Copaxone
    • Fingolimod (FTY720)
    • BG-12 (Phase III)
    • Laquinimod (Phase III)
    • Teriflunomide
    • Oral Leustatin
  • Interferon Beta
    • Avonex
    • Rebif
    • Betaseron / Betaferon
  • Monoclonal antibodies
    • Rituxan
    • HuMax CD
    • Campath
    • Tysabri
    • SB689699
  • Other MS Therapies
    • Dirucotide (MBP8298)
    • Fampridine SR
• Parkinson's
  • Dopamineric drugs
    • Apokyn
    • Mirapex
    • Sinemet
    • Requip XL
    • Comtan / Stavelo
  • Other Drugs
    • Agilect / Azilect
    • ACP-103
    • Droxidopa